Nexus Pharmaceuticals Receives FDA Approval for Arsenic Trioxide Injection in 10mg per 10mL Vial
19 November 2018 - - US-based healthcare company Nexus Pharmaceuticals has launched Arsenic Trioxide Injection, with immediate availability in the United States, the company said.

Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10mg per 10mL vial for injection.

The product is the AP rated generic alternative of TRISENOX indicated for relapsed or refractory acute promyelocytic leukemia.

Arsenic Trioxide Injection is indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

Nexus Pharmaceuticals, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice.

Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they're needed most.